Can I Buy Mylan NV Ord Shs Shares in India?

Yes, Mylan NV Ord Shs shares can be bought in India by opening an international trading account with Groww.

How to Buy Mylan NV Ord Shs Shares in India?

One can easily invest in Mylan NV Ord Shs shares from India by: Direct Investment - Opening an international trading account with Groww which includes KYC verification in the US. Your account gets activated in a few minutes to a few hours, after which you can start adding funds in USD balance to buy Mylan NV Ord Shs shares. Indirect Investment - Under this form of investment, you can choose either a Mutual Fund (MF) or an Exchange-Traded Fund (ETF) that invests in global shares and start investing in shares of Mylan NV Ord Shs.

What is the Share Price of Mylan NV Ord Shs?

The share price of Mylan NV Ord Shs is in Dollars and if you are investing from India, you can always check the INR valuation before investing. The current Mylan NV Ord Shs share price is $15.86 as of 19 Apr ‘24

What is the Market Cap of Mylan NV Ord Shs?

The Mylan NV Ord Shs market cap is $8.58B as of 19 Apr ‘24

What is the PE and PB ratio of Mylan NV Ord Shs?

The PE and PB ratio of Mylan NV Ord Shs is 32.2 and 0.7 as of 19 Apr ‘24

Mylan NV Ord Shs Share Price, MYL Stock Price Quote Today

<img alt="Mylan NV Ord Shs" srcSet="https://viewlogo.s3.amazonaws.com/62096/conversions/256181-default.png 1x, https://viewlogo.s3.amazonaws.com/62096/conversions/256181-default.png 2x" src="https://viewlogo.s3.amazonaws.com/62096/conversions/256181-default.png" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="companyLogo_companyImage__bT0On absolute-center uspp14Logo" loading="lazy"/>
Mylan NV Ord Shs Healthcare 
$15.86
+0.30(1.96%) 1D
1D
1W
1M
1Y
3Y
5Y
Performance
Open PricePrev. CloseVolumeAvg. Volume
$15.64$15.8626,573,5866,465,671
FundamentalsMarket Cap$8.58B
P/B Ratio0.7
P/E Ratio32.2
Enterprise Value$20.26B
Div. Yield0.00%
Book Value24.27
EPS(TTM)0.36
ROENA
Understand Fundamentals
FUNDAMENTALS
It is financial information that is reported quarterly or annually.
Market Cap
Market cap or market capitalization is the total market value of all of a company's outstanding shares.
Div. Yield
The divided yield displayed as a percentage is the amount of money a company pays shareholders for owning a share of its stock divided by its current stock price
P/B Ratio
The price-to-book ratio is a company's current market price to its Book Value. Traditionally, any value under 1.0 is considered a good P/B value, indicating a potentially undervalued stock.
Book Value
The book value of a stock is theoretically the amount of money that would be paid to shareholders if the company was liquidated and paid off all of its liabilities.
P/E Ratio
The price-earnings ratio is a company's share price to the company's Earnings per Share. The ratio is used for evaluating companies and to find out whether they are overvalued or undervalued.
EPS(TTM)
Earnings per share (EPS) is a company's net profit divided by the number of common shares it has outstanding. EPS indicates how much money a company makes for each share of its stock, and is widely used metric to estimate corporate value
Enterprise Value
Enterprise Value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
ROE
Return on equity (ROE) is a measure of financial performance calculated by dividing net income by shareholder's equity
About the CompanyMylan N.V. was a generic and specialty pharmaceuticals company headquartered in Canonsburg, Pennsylvania. In November 2020, the company merged with Upjohn, a division of Pfizer to form Viatris. Mylan N.V. shares were traded on NASDAQ under the ticker symbol “MYL”. It was engaged in the manufacturing, marketing and distribution of pharmaceutical products.
Milan Puskar and Don Panoz founded MYL in 1961 as Milan Pharmaceuticals. Fifteen years later, it relocated its headquarters from White Sulphur Springs, West Virginia to Canonsburg.
In February, 1973, Mylan moved to the OTC market, and three years later, it moved to NASDAQ. Following the move, MYL shares became a component of the S&P 500 and NASDAQ Biotechnology indices. In 2011, it launched a generic variant of famciclovir, a guanosine analogue antiviral drug. In 1980, MYL decided to market products under their own brand name. In 1984, MYL received approval for its first drug, Maxzide which was meant for treating hypertension. This was also the first-ever drug to be patented by a company that manufactures generic drugs.
Since its inception, Mylan NV has completed the acquisition of over 10 companies. Two of such acquisitions involved private equity firms. Medical products and life science are the two main sectors that are targeted by the company. MYL has acquired companies in more than 4 states in America. In 1993, MYL completed the acquisition of Bertek Inc. Three years later, it acquired UDL Laboratories that engaged in providing generic medications to healthcare facilities.
Mylan completed its largest acquisition to date when it acquired Merck Generics in 2007 for approximately $5.5 billion. Upon successful completion of the acquisition, Mylan Laboratories Inc. was renamed to Mylan Technologies Inc. In 2011, it secured a contract with Pfizer, an American multinational pharmaceutical company for the exclusive rights to produce, market and distribute Pfizer’s generic equivalent to GSK Group’s Seretide Diskus and Advair Diskus. Moreover, MYL also incorporated a Pfizer-owned dry powder inhaler delivery platform. In February 2012, Mylan Institutional business was the recipient of Novation’s Pharmacy Generic Supplier of the Year Award. It was presented to Mylan at Novation’s Annual Supplier Summit which was held on February 22, 2012. In 2020 Mylan Inc. was ranked 396th on the list of Fortune 500 companies.;
OrganisationMylan NV Ord Shs
IndustryDrug Manufacturers—Specialty & Generic
HeadQuartersHatfield
Company Financials
*All values are in Million $
No Graph Data To Display
Quarterly
Yearly
See Details
Similar StocksCOMPANYMARKET PRICECLOSE PRICEMARKET CAP

Invest the way you want

Join millions of Indians who trust and love Groww

Explore Products

Vaishnavi Tech Park, 3rd & 4th Floor
Sarjapur Main Road, Bellandur
Bengaluru – 560103
Contact Us
PRODUCTS
StocksFutures & OptionsIPOMutual FundsCreditBill Payments
GROWW
About UsPricingBlogMedia & PressCareersHelp and SupportTrust and Safety
QUICK LINKS
AMC Mutual FundsCalculatorsGlossaryOpen Demat AccountGroww DigestSitemapIncome Tax Calculator
ⓒ 2016-2024 Groww. All rights reserved, Built with ♥in India

Open Price	Prev. Close	Volume	Avg. Volume
$15.64	$15.86	26,573,586	6,465,671

Market Cap	$8.58B
P/B Ratio	0.7
P/E Ratio	32.2
Enterprise Value	$20.26B

Organisation	Mylan NV Ord Shs
Industry	Drug Manufacturers—Specialty & Generic
HeadQuarters	Hatfield